Aspirin Dose for the Prevention of Cardiovascular Disease

Abstract

Currently available clinical data do not support the routine, long-term use of aspirin dosages greater than 75 to 81 mg/d in the setting of cardiovascular disease prevention. Higher dosages, which may be commonly prescribed, do not better prevent events but are associated with increased risks of gastrointestinal bleeding.

Keywords

MedicineAspirinDoseClinical trialPlatelet aggregation inhibitorDiseaseIncidence (geometry)MEDLINEIntensive care medicinePharmacologyInternal medicine

Affiliated Institutions

Related Publications

Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease

Lars Wallentin , Christoph Varenhorst , Stefan James +6 more

In aspirin-treated subjects with coronary artery disease, prasugrel 60/10 mg provides faster onset and greater inhibition of P2Y(12) receptor-mediated platelet aggregation than ...

2007 European Heart Journal 455 citations

Inhibitory effect of clopidogrel on platelet adhesion and intimal proliferation after arterial injury in rabbits.

Jean‐Marc Herbert , A Tissinier , G. Defreyn +1 more

The possible activity of ticlopidine and its analogue clopidogrel in early atherogenesis was investigated. Incubation of rabbit platelets with the extracellular matrix produced ...

1993 Arteriosclerosis and Thrombosis A Jou... 104 citations

Increased Mortality With Oral Platelet Glycoprotein IIb/IIIa Antagonists

Derek P. Chew , Deepak L. Bhatt , Shelly Sapp +1 more

Background —Numerous clinical trials have established the benefits of intravenous glycoprotein IIb/IIIa inhibition in the management of coronary artery disease. In contrast, the...

2001 Circulation 358 citations

Pharmacology of CS-747 (prasugrel, LY640315), a Novel, Potent Antiplatelet Agent with in Vivo P2Y<sub>12</sub>Receptor Antagonist Activity

Y. Niitsu , Joseph A. Jakubowski , Atsuhiro Sugidachi +1 more

CS-747 (prasugrel, LY640315) is a member of the thienopyridine class of oral platelet aggregation inhibitors that includes ticlopidine and clopidogrel. A single oral administrat...

2005 Seminars in Thrombosis and Hemostasis 233 citations

Controlled trial of high-versus low-dose aspirin treatment after percutaneous transluminal angioplasty in patients with peripheral vascular disease

C. Rankel , A Creutzig , G. Luska +7 more

Percutaneous transluminal angioplasty of aortoiliac and femoropopliteal atherosclerotic lesions can provide long-lasting hemodynamic improvement. High-dose aspirin is commonly p...

1994 Journal of Molecular Medicine 43 citations

Publication Info

Year: 2007
Type: review
Volume: 297
Issue: 18
Pages: 2018-2018
Citations: 444
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Aspirin Dose for the Prevention of Cardiovascular Disease

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

444

OpenAlex

Cite This

APA Style

                            
                                
                                    Charles L. Campbell, 
                                
                                    Susan S. Smyth, 
                                
                                    Gilles Montalescot
                                
                                et al.
                            
                            (2007). 
                            Aspirin Dose for the Prevention of Cardiovascular Disease. 
                            JAMA
                            , 297
                            (18)
                            , 2018-2018.
                            https://doi.org/10.1001/jama.297.18.2018
                        

Identifiers

DOI: 10.1001/jama.297.18.2018